Respiratory syncytial virus (RSV) is a common, highly contagious illness that affects the nose, throat, and lungs. Although RSV usually causes mild illness with cold-like symptoms, the infection can ...

New real-world data suggests that seniors who get the RSV vaccine have an 80% lower odds for severe illness It's yet another reason to get immunized ahead of another RSV season Widespread immunization ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more. Alnylam Pharmaceuticals is expanding the footprint of its RNA-based ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

These stocks have increased dividends consecutively for 50-plus years.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Upgrade to begin using 40 years of financial statements and get so much more. Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all ...

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its ...